Biomarkers /
MCL1
Overview
Myeloid cell leukemia 1 (MCL1) is a gene that encodes a protein that inhibits apoptotic cell death. Missense mutations, nonsense mutations, silent mutations, and in-frame deletions are observed in cancers such as bone cancer, eye cancer, and lung cancer.
MCL1 is altered in 1.86% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, bladder urothelial carcinoma, high grade ovarian serous adenocarcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in MCL1 are MCL1 Amplification (1.30%), MCL1 Loss (0.19%), MCL1 D72G (0.05%), MCL1 E41K (0.04%), and MCL1 L21_G24del (0.02%) [3].
Clinical Trials
Significance of MCL1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.